Patient understanding and acceptability of an early lung cancer diagnosis trial: a qualitative study

Hayley C Prout, Allan Barham, Emily Bongard, Rhiannon Tudor-Edwards, Gareth Griffiths, Willie Hamilton, Emily Harrop, Kerry Hood, Chris N Hurt, Rosie Nelson, Catherine Porter, Kirsty Roberts, Trevor Rogers, Emma Thomas-Jones, Angela Tod, Seow Tien Yeo, Richard D Neal, Annmarie Nelson, Hayley C Prout, Allan Barham, Emily Bongard, Rhiannon Tudor-Edwards, Gareth Griffiths, Willie Hamilton, Emily Harrop, Kerry Hood, Chris N Hurt, Rosie Nelson, Catherine Porter, Kirsty Roberts, Trevor Rogers, Emma Thomas-Jones, Angela Tod, Seow Tien Yeo, Richard D Neal, Annmarie Nelson

Abstract

Background: The ELCID (Early Lung Cancer Investigation and Diagnosis) trial was a feasibility randomised controlled trial examining the effect on lung cancer diagnosis of lowering the threshold for referral for urgent chest x-ray for smokers and recent ex-smokers, aged over 60 years with new chest symptoms. The qualitative component aimed to explore the feasibility of individually randomising patients to an urgent chest x-ray or not and to investigate any barriers to patient recruitment and participation. We integrated this within the feasibility trial to inform the design of any future definitive trial, particularly in view of the lack of research exploring symptomatic patients' experiences of participating in diagnostic trials for possible/suspected lung cancer. Although previous studies contributed valuable information concerning screening for lung cancer and patient participation in trials, this paper is the first to explore issues relating to this specific patient group.

Methods: Qualitative interviews were conducted with 21 patients, comprising 9 who had been randomised to receive an immediate chest x-ray, 10 who were randomised to receive the standard treatment according to the National Institute for Health and Care Excellence guidelines, and 2 who chose not to participate in the trial. Interviews were analysed using a framework approach.

Results: The findings of this analysis showed that altruism, personal benefit and the reassurance of not having lung cancer were important factors in patient participation. However, patients largely believed that being in the intervention arm was more beneficial, highlighting a lack of understanding of clinical equipoise. Disincentives to participation in the trial included the stigmatisation of patients who smoked (given the inclusion criteria). Although the majority of patients reported that they were happy with the trial design, there was evidence of poor understanding. Last, for several patients, placing trust in health professionals was preferred to understanding the trial processes.

Conclusions: The integration of a qualitative study focusing on participant experience as a secondary outcome of a feasibility trial enabled exploration of patient response to participation and recruitment. The study demonstrated that although it is feasible to recruit patients to the ELCID trial, more work needs to be done to ensure an understanding of study principles and also of smoking stigmatisation.

Trial registration: ClinicalTrials.gov, NCT01344005 . Registered on 27 April 2011.

Keywords: Feasibility studies; Lung neoplasms; Patient preference; Primary healthcare; Qualitative research; Quality of life; Random allocation; Referral and consultation; Smoking; X-rays.

Conflict of interest statement

NHS ethics was approved by the North Wales Research Ethics Committee (11/WA/022) on the 25 August 2011. This included the qualitative substudy for all the centres involved. We also obtained informed consent from each participant recruited into the study.

This qualitative study used anonymized quotes from study participants. Participants consented to their anonymized quotes being reported.

The authors declare that they have no competing interests.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Recruitment and randomisation of patients
Fig. 2
Fig. 2
Recruitment of patients for the qualitative interview study

References

    1. Cancer Research UK. Lung cancer statistics. . Accessed 25 July 2018.
    1. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):23–34. doi: 10.1016/S1470-2045(13)70546-1.
    1. National Awareness and Early Diagnosis Initiative (NAEDI). . Accessed 25 July 2018.
    1. Welsh government. Together for health – cancer delivery plan: a delivery plan up to 2016 for NHS Wales and its partners: the highest standard of care for everyone with cancer. . Accessed 25 July 2018.
    1. Guldbrandt LM, Rasmussen TR, Rasmussen F, Vedsted P. Implementing direct access to low-dose computed tomography in general practice—method, adaption and outcome. PLoS One. 2014;9(11):e112162. doi: 10.1371/journal.pone.0112162.
    1. National Lung Screening Trial Research Team Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980–1991. doi: 10.1056/NEJMoa1209120.
    1. Athey VL, Suckling RJ, Tod AM, Walters SJ, Rogers TK. Early diagnosis of lung cancer: evaluation of a community-based social marketing intervention. Thorax. 2012;67(5):412–417. doi: 10.1136/thoraxjnl-2011-200714.
    1. Ironmonger L, Ohuma E, Ormiston-Smith N, Gildea C, Thomson CS, Peake MD. An evaluation of the impact of large-scale interventions to raise public awareness of a lung cancer symptom. Br J Cancer. 2015;112(1):207–216. doi: 10.1038/bjc.2014.596.
    1. Neal RD, Barham A, Bongard E, Edwards RT, Fitzgibbon J, Griffiths G, Hamilton W, Hood K, Nelson A, Parker D, et al. Immediate chest X-ray for patients at risk of lung cancer presenting in primary care: randomised controlled feasibility trial. Br J Cancer. 2017;116(3):293–302. doi: 10.1038/bjc.2016.414.
    1. Hurt CN, Roberts K, Rogers T, Griffiths GO, Hood K, Prout H, Nelson A, Fitzgibbon J, Barham A, Thomas-Jones E. Protocol for a feasibility clinical trial examining the effect on lung cancer diagnosis of offering a chest X-ray to higher risk patients with chest symptoms. Trials. 2013;14:405. doi: 10.1186/1745-6215-14-405.
    1. Birt L, Hall N, Emery J, Banks J, Mills K, Johnson M, Hamilton W, Walter FM. Responding to symptoms suggestive of lung cancer: a qualitative interview study. BMJ Open Respir Res. 2014;1(1):e000067. doi: 10.1136/bmjresp-2014-000067.
    1. Banks J, Hollinghurst S, Bigwood L, Peters TJ, Walter FM, Hamilton W. Preferences for cancer investigation: a vignette-based study of primary-care attendees. Lancet Oncol. 2014;15(2):232–240. doi: 10.1016/S1470-2045(13)70588-6.
    1. Banks J, Walter FM, Hall N, Mills K, Hamilton W, Turner KM. Decision making and referral from primary care for possible lung and colorectal cancer: a qualitative study of patients’ experiences. Br J Gen Pract. 2014;64(629):e775–e782. doi: 10.3399/bjgp14X682849.
    1. Rankin NM, York S, Stone E, Barnes D, McGregor D, Lai M, Shaw T, Butow PN. Pathways to lung cancer diagnosis: a qualitative study of patients and general practitioners about diagnostic and pretreatment intervals. Ann Am Thorac Soc. 2017;14(5):742–753. doi: 10.1513/AnnalsATS.201610-817OC.
    1. Sibbald B, Roland M. Understanding controlled trials: why are randomised controlled trials important? BMJ. 1998;316(7126):201. doi: 10.1136/bmj.316.7126.201.
    1. Akobeng AK. Understanding randomised controlled trials. Arch Dis Child. 2005;90(8):840–844. doi: 10.1136/adc.2004.058222.
    1. Stang A. Randomized controlled trials—an indispensible part of clinical research. Dtsch Arztebl Int. 2011;108(39):661–2.
    1. Nelson A, Fenlon D, Morris J, Sampson C, Harrop E, Murray N, Wheatley D, Hood K, Griffiths G, Barrett-Lee P. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials. 2013;14(1):325. doi: 10.1186/1745-6215-14-325.
    1. Harrop E, Noble S, Edwards M, Sivell S, Moore B, Nelson A, FRAGMATIC Trial Management Group (TMG) “I didn’t really understand it, I just thought it’d help”: exploring the motivations, understandings and experiences of patients with advanced lung cancer participating in a non-placebo clinical IMP trial. Trials. 2016;17:329. doi: 10.1186/s13063-016-1460-8.
    1. Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, Frankel S, Neal D, Hamdy F. Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ. 2002;325(7367):766–770. doi: 10.1136/bmj.325.7367.766.
    1. Mills N, Donovan JL, Smith M, Jacoby A, Neal DE, Hamdy FC. Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. Control Clin Trials. 2003;24(3):272–282. doi: 10.1016/S0197-2456(03)00020-5.
    1. Noble SI, Nelson A, Fitzmaurice D, Bekkers M-J, Baillie J, Sivell S, Canham J, Smith JD, Casbard A, Cohen A. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technol Assess. 2015;19(83)
    1. Harrop E, Kelly J, Griffiths G, Casbard A, Nelson A. Why do patients decline surgical trials? Findings from a qualitative interview study embedded in the Cancer Research UK BOLERO trial (Bladder cancer: Open versus Laparoscopic or RObotic cystectomy) Trials. 2016;17:35. doi: 10.1186/s13063-016-1173-z.
    1. Paramasivan S, Huddart R, Hall E, Lewis R, Birtle A, Donovan JL. Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011) Trials. 2011;12:78. doi: 10.1186/1745-6215-12-78.
    1. Maughan T, Meade A, Adams R, Richman S, Butler R, Fisher D, Wilson R, Jasani B, Taylor G, Williams G. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine. Br J Cancer. 2014;110(9):2178–2186. doi: 10.1038/bjc.2014.182.
    1. Adamson D, Blazeby J, Nelson A, Hurt C, Nixon L, Fitzgibbon J, Crosby T, Staffurth J, Evans M, Kelly NH. Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: radiotherapy after Oesophageal Cancer stenting): study protocol for a randomized controlled trial. Trials. 2014;15(1):402. doi: 10.1186/1745-6215-15-402.
    1. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357. doi: 10.1093/intqhc/mzm042.
    1. Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82. doi: 10.1177/1525822X05279903.
    1. NVivo. Qualitative data analysis software. . Accessed 25 July 2018.
    1. Ritchie J, Spencer L, Bryman A, Burgess RG. Analyzing qualitative data. London: Routledge; 1994. p. 173–94.
    1. Locock L, Smith L. Personal experiences of taking part in clinical trials – a qualitative study. Patient Educ Couns. 2011;84(3):303–309. doi: 10.1016/j.pec.2011.06.002.
    1. Lilford RJ. Ethics of clinical trials from a Bayesian and decision analytic perspective: whose equipoise is it anyway? BMJ. 2003;326(7396):980–1. doi: 10.1136/bmj.326.7396.980.
    1. Donovan JL, Brindle L, Mills N. Capturing users’ experiences of participating in cancer trials. Eur J Cancer Care. 2002;11(3):210–214. doi: 10.1046/j.1365-2354.2002.00341.x.
    1. Featherstone K, Donovan JL. “Why don’t they just tell me straight, why allocate it?” The struggle to make sense of participating in a randomised controlled trial. Soc Sci Med. 2002;55(5):709–719. doi: 10.1016/S0277-9536(01)00197-6.
    1. das Nair R, Orr KS, Vedhara K, Kendrick D. Exploring recruitment barriers and facilitators in early cancer detection trials: the use of pre-trial focus groups. Trials. 2014;15:98. doi: 10.1186/1745-6215-15-98.
    1. Featherstone K, Donovan JL. Random allocation or allocation at random? Patients' perspectives of participation in a randomised controlled trial. BMJ. 1998;317(7167):1177–1180. doi: 10.1136/bmj.317.7167.1177.
    1. Behrendt C, Gölz T, Roesler C, Bertz H, Wünsch A. What do our patients understand about their trial participation? Assessing patients' understanding of their informed consent consultation about randomised clinical trials. J Med Ethics. 2011;37(2):74–80. doi: 10.1136/jme.2010.035485.
    1. Tam NT, Huy NT, Thoa LTB, Long NP, Trang NTH, Hirayama K, Karbwang J. Participants’ understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis. Bull World Health Organ. 2015;93(3):186–198H. doi: 10.2471/BLT.14.141390.
    1. Doyal L. Informed consent: moral necessity or illusion? Qual Health Care. 2001;10(Suppl 1):i29–i33. doi: 10.1136/qhc.0100029.

Source: PubMed

3
구독하다